Combination Product Design and Component Quality Control Policy

Educational Training Module: Combination Product Design and Component Quality Control Policy

1. Learning Objectives

Learning objectives serve as the essential roadmap for the trainee, providing a structured path that ensures the transition from academic theory to practical industrial application is both measurable and targeted. By defining clear outcomes, we ensure that every participant understands the specific regulatory and operational standards required at DP-MFG-FACILITY to maintain the integrity of complex therapeutic products.

Upon completion of this module, the trainee will be able to:

1. Distinguish between "Constituent Parts" and "Component Parts" to accurately identify regulatory identities versus physical assembly elements within a combination product.
2. Identify the specific regulatory requirements that govern the facility's practices, specifically 21 CFR Parts 210, 211, 820.30, 820.50, 21 CFR 600–680 (Biological Products), and EU Annex 8.
3. Explain the scope of the policy, including the specific exclusion of syringes not assembled into a device and their alignment with USP/EP requirements.
4. Describe the relationship between design controls (820.30) and technical transfer, specifically how the facility ensures design criticalities are integrated into manufacturing specifications.

Achieving these objectives is the first step toward understanding the broader Quality Management System (QMS) and your role within it.

2. Where This Policy Sits in the Quality System

The strategic importance of document hierarchy in a Current Good Manufacturing Practice (cGMP) environment cannot be overstated. This structure ensures consistency, provides a clear chain of command for procedural requirements, and safeguards regulatory compliance by organizing information from high-level intent to granular execution.

The document hierarchy is generally structured as follows:

• Policy: Represents management’s "what and why"—the high-level intent, commitments, and governing principles.
• Standard Operating Procedure (SOP): Defines the "how"—the specific steps required to execute the policy.
• Work Instruction (WI): Provides detailed, task-specific directions.
• Records: Offers the "evidence"—the proof that the procedures were followed.

This specific Policy acts as the governing document for how the facility ensures device design specifications are met during incoming inspection and technical transfer. It establishes the high-level mandate that all manufacturing and quality activities must follow to remain compliant with drug, biologic, and device regulations.

Before understanding the technical "how" of daily operations, one must grasp the high-level "why" behind the policy's existence.

3. Why This Policy Matters

This policy acts as a fundamental safeguard for patient safety and product SISPQ (Strength, Identity, Safety, Purity, Quality). In the world of combination products—where drugs, biologics, and devices intersect—any failure in design integrity or component quality can have catastrophic consequences for the end-user.

Using the framework of this policy, we address several critical risks:

• Patient Safety: If device constituent parts fail to meet design specifications, the delivery of the drug or biologic may be compromised, leading to incorrect dosing or device failure.
• Management Responsibility: This policy fulfills the management mandate to ensure that the combination of drug, device, or biologic remains effective throughout its lifecycle.
• Bridge to Reality: This policy is the essential bridge between design intent (what the product is supposed to be) and manufacturing reality (what is actually produced). It ensures that the license holder's design is accurately reflected in the physical product.

Clear definitions and principles are required to ensure all personnel are speaking the same regulatory language and maintaining these high standards.

4. Key Terms & Definitions

Precise terminology is the bedrock of data integrity and clear communication in a sterile manufacturing facility. To ensure compliance, we must utilize the specific definitions established by regulatory bodies and our internal quality standards.

• Combination Product: A product comprised of two or more regulated components (drug/device, biologic/device, drug/biologic, or drug/device/biologic). These can be:
  • Single-entity: Physically or chemically combined as one unit.
  • Co-packaged: Separate products packaged together in a single unit.
  • Cross-labeled: Separately packaged products intended for use only with another specifically named product to achieve the intended effect.
• Constituent Part: An article in a combination product distinguishable by its regulatory identity as a drug, device, or biological product (e.g., the drug itself or the device it is in).
• Component Part: A part that makes up the device constituent part of a combination product.
• Biological Product: A virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product applicable to the prevention, treatment, or cure of a disease or condition of human beings.
• Device: An instrument, apparatus, or similar article, including any component, part, or accessory, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, which does not achieve its primary purpose through chemical action or metabolism.
• Drug: (A) Articles recognized in official pharmacopoeias; (B) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease; (C) articles intended to affect the structure or function of the body; and (D) articles intended for use as a component of any article specified in clause (A), (B), or (C).
• Primary Manufacturing: Drug product manufacturing, including formulation, filling, and container closure.
• Secondary Manufacturing: Drug product manufacturing that includes device assembly, accessorization, and packaging.
• SISPQ: An acronym for Strength, Identity, Safety, Purity, and Quality.
• AQL: Acceptable Quality Limit.